Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04000152




Registration number
NCT04000152
Ethics application status
Date submitted
25/06/2019
Date registered
27/06/2019

Titles & IDs
Public title
RCT Study to Validate niPGT-A Clinical Benefit.
Scientific title
Randomized Controlled Clinical Study to Assess the Benefit of Non-invasive PGT-A, by the Analysis of Spent Blastocyst Media, as a Tool for Embryo Prioritization in Infertile Patients Undergoing Assisted Reproduction.
Secondary ID [1] 0 0
IGX1-NIP-CS-18-05
Universal Trial Number (UTN)
Trial acronym
niPGT-A_RCT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aneuploidy 0 0
Chromosome Abnormality 0 0
Infertility 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Diagnosis / Prognosis - niPGT-A
Other interventions - Morphology criteria

Active comparator: Control group (group 1) - Deferred single day 6/7 blastocyst transfer with blastocyst selection according to morphology.

Experimental: Intervention group (group 2) - Deferred single day 6/7 blastocyst transfer with blastocyst selection according to the analysis of the spent culture media (niPGT-A).


Diagnosis / Prognosis: niPGT-A
Two scenarios should be considered according to the results in the SBM analysis:

1. The couple decides to transfer the blastocyst selected according to the SBM result (blastocyst prioritization system).
2. The couple decides to biopsy the blastocysts (if SBM results show low euploidy score). This PGT-A analysis will be offered for free but the outcome of these transfers will be excluded for the analysis per completed protocol. However, all transfers will be included in the intention-to-treat analysis.

In the exceptional case of getting a non-informative result for all the SBM analysed, the niPGT-A could be performed again on new SBM samples collected after an additional culture of the embryos for, at least, 8 hours.

Other interventions: Morphology criteria
Embryos for transfer will be selected by the only applicable technique, the assessment of morphology according to Gardner´s criteria, which is the most standardized method.
Intervention code [1] 0 0
Diagnosis / Prognosis
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Non-invasive analysis of the chromosomal status of the embryo
Timepoint [1] 0 0
7 days
Primary outcome [2] 0 0
Ongoing pregnancy rate
Timepoint [2] 0 0
Over 12 weeks
Secondary outcome [1] 0 0
NGS results of the SBM
Timepoint [1] 0 0
7 days at least
Secondary outcome [2] 0 0
Non-Invasive Prenatal Testing (NIPT)
Timepoint [2] 0 0
Up to 12 weeks
Secondary outcome [3] 0 0
Clinical miscarriage rate
Timepoint [3] 0 0
Up to 6 months after the ovum pick-up
Secondary outcome [4] 0 0
Analysis of the Products of Conception (POC)
Timepoint [4] 0 0
Up to 20 weeks
Secondary outcome [5] 0 0
Cumulative ongoing pregnancy rate
Timepoint [5] 0 0
Over 6 months after the ovum pick-up
Secondary outcome [6] 0 0
Time to get an ongoing pregnancy
Timepoint [6] 0 0
Up to 6 months after the ovum pick-up
Secondary outcome [7] 0 0
Live birth rate
Timepoint [7] 0 0
Over 40 weeks
Secondary outcome [8] 0 0
Cumulative live birth rate
Timepoint [8] 0 0
Over 6 months after the ovum pick-up
Secondary outcome [9] 0 0
Obstetrical outcomes comparison
Timepoint [9] 0 0
Over 40 weeks

Eligibility
Key inclusion criteria
* Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
* IVF patients intending to undergo deferred day 6/7 blastocyst SET for any medical indication.
* All the oocytes/embryos from the cycle should follow the laboratory protocol described in the study (embryo culture and vitrification on day 6/7).
* ICSI, IVF or ICSI/IVF performed in fresh own oocytes from couples not undergoing PGT-A. Note: Donor sperm is allowed.
* Female age: 20-40 years, both included.
Minimum age
20 Years
Maximum age
40 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Assisted hatching and artificial collapse before collecting SBM samples. Note: Both procedures are allowed only after collecting the culture media sample.
* A known abnormal karyotype if the couple provides it at consultation. If not, karyotype is not compulsory.
* Couples planning to undergo PGT-M or PGT-SR cases will be excluded.
* Surrogate pregnancy (in those countries where it is allowed).
* ERA test and embryo transfer according to ERA result.
* Time-lapse culture systems are not allowed after day 4 of culture.
* Presence of pathologies or malformations that affect the uterine cavity such as polyps, intramural myomas = 4cm or submucosal, septum or hydrosalpinx during the patient's participation in the study. Patients suffering these pathologies before or after their inclusion in the study can participate if the pathology is corrected before performing any study procedure.
* Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/06/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
1108
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Massachusetts
Country [2] 0 0
Argentina
State/province [2] 0 0
Buenos Aires
Country [3] 0 0
Argentina
State/province [3] 0 0
Salta
Country [4] 0 0
Brazil
State/province [4] 0 0
Porto Alegre
Country [5] 0 0
Brazil
State/province [5] 0 0
Rio De Janeiro
Country [6] 0 0
France
State/province [6] 0 0
Suresnes
Country [7] 0 0
Italy
State/province [7] 0 0
Bologna
Country [8] 0 0
Italy
State/province [8] 0 0
Firenze
Country [9] 0 0
Italy
State/province [9] 0 0
Torino
Country [10] 0 0
Spain
State/province [10] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Igenomix
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Carmen Rubio, PhD
Address 0 0
Igenomix S.L.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Carlos Gómez, BSc MSc
Address 0 0
Country 0 0
Phone 0 0
+34 963905310
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04000152